SCHEMBL161026

SCHEMBL161026

CCNC(=O)c1cccc(O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.65
ALDH1A1 P00352 1/20 0.65
EGLN2 Q96KS0 1/20 0.61
SMN1; SMN2 Q16637 2/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C19 P33261 1/20 0.54
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA6 P23280 1/20 0.52
CA9 Q16790 1/20 0.52
GAA P10253 2/20 0.51
HSD17B10 Q99714 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
OPRM1 P35372 2/20 0.50
OPRD1 P41143 2/20 0.50
PARP1 P09874 1/20 0.50
NAMPT P43490 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13702348 0.90 CDK8 (0.56) KDM4EALDH1A1EGLN2SMN1; SMN2KMT2A
SCHEMBL9713054 0.88 SMN1; SMN2 (0.67) ALDH1A1SMN1; SMN2KMT2AMEN1CYP1A2
SCHEMBL163436 0.86 L3MBTL1 (0.71) KDM4EALDH1A1EGLN2SMN1; SMN2KMT2A
SCHEMBL23484191 0.85 KDM4E (0.69) KDM4EALDH1A1EGLN2SMN1; SMN2KMT2A
SCHEMBL161905 0.83 SMN1; SMN2 (0.81) KDM4EALDH1A1EGLN2SMN1; SMN2GAA
SCHEMBL13445829 0.82 GAA (0.53) KDM4EALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL13577926 0.82 SMN1; SMN2 (0.73) KDM4EALDH1A1EGLN2SMN1; SMN2GAA
SCHEMBL13702385 0.82 MEN1 (0.61) KDM4EALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5426936 0.81 L3MBTL1 (0.75) KDM4EALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL1360195 0.81 HDAC8 (0.65) SMN1; SMN2KMT2AMEN1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116669554-A Use of Dhodh inhibitors for controlling resistant phytopathogenic fungi in crops 拜耳公司 2023-08-29 CN disclosed
US-20230192904-A1 BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF THE BROAD INSTITUTE, INC. 2023-06-22 US disclosed
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20170081346-A1 MESOSCOPIC MATERIALS COMPRISED OF ORDERED SUPERLATTICES OF MICROPOROUS METAL-ORGANIC FRAMEWORKS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-03-23 US disclosed
US-20160266133-A1 NUCLEIC ACID-SCAFFOLDED SMALL MOLECULE LIBRARIES ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2016-09-15 US disclosed
WO-2016004093-A2 THERAPEUTIC COMPOSITIONS INCLUDING GALECTIN-3 INHIBITORS AND USES THEREOF STEALTH BIOTHERAPEUTICS CORP (MC) 2016-01-07 WO disclosed
WO-2015161037-A1 VERY LOW DENSITY METAL ORGANIC FRAMEWORKS WITH LARGE PORE VOLUMES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-10-22 WO disclosed
WO-2014020043-A1 COMBINATIONS FOR THE TREATMENT OF CANCER BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-02-06 WO disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors FLECK ROMAN WOLFGANG 2009-09-10 US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081346-A1 MESOSCOPIC MATERIALS COMPRISED OF ORDERED SUPERLATTICES OF MICROPOROUS METAL-ORGANIC FRAMEWORKS MCM2, YTHDF2, MCM6 KDM4E 1665/4885ALDH1A1 2926/4885EGLN2 3977/4885
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 KDM4E 2214/4885ALDH1A1 1667/4885EGLN2 2258/4885
US-20160266133-A1 NUCLEIC ACID-SCAFFOLDED SMALL MOLECULE LIBRARIES SNRPE, SARNP, SARS1 KDM4E 4277/4885ALDH1A1 4550/4885EGLN2 2529/4885
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors EPHX1, EPHX2, EPX KDM4E 1988/4885ALDH1A1 376/4885EGLN2 200/4885
US-20230192904-A1 BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF ERBB2, ACP1, TK1 KDM4E 2301/4885ALDH1A1 2221/4885EGLN2 4007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.